Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arbutus BiopharmaABUS +0.23%51 3-Year EBITDA Growth Rate is 25.10% as of Mar. 2026, which is 116% above its 10-year median of 11.60. GuruFocus rates ABUS with a GF Score™ of 51/100 and a GF Value™ of $50.40 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,136 Biotechnology companies, Arbutus Biopharma ranks better than 61.36% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 25.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 23.10% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 25.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Arbutus Biopharma was 47.60% per year. The lowest was -130.20% per year. And the median was 11.60% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Arbutus Biopharma 3-Year EBITDA Growth Rate Related Terms
ABUS vs TBPH, ANNX, SANA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Arbutus Biopharma's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arbutus Biopharma 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Arbutus Biopharma's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 25.10% mean?
Arbutus Biopharma (ABUS) has a 3-Year EBITDA Growth Rate of 25.10% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Arbutus Biopharma and its competitors. This is 116% above median its historical median of 11.60. According to the industry distribution chart, Arbutus Biopharma ranks #439 out of 1136 companies in the Biotechnology industry, placing it in the top 38.6%.
Is Arbutus Biopharma's 3-Year EBITDA Growth Rate too high?
Arbutus Biopharma's current 3-Year EBITDA Growth Rate of 25.10% is 116% above median its 10-year median of 11.60. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Arbutus Biopharma's value of 25.10% is 69% above this industry median. Based on the distribution chart, Arbutus Biopharma ranks #439 out of 1136 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Arbutus Biopharma has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arbutus Biopharma's 3-Year EBITDA Growth Rate compare to TBPH and ANNX?
According to the Biotechnology industry distribution chart, Arbutus Biopharma ranks #439 out of 1136 companies for 3-Year EBITDA Growth Rate. This puts Arbutus Biopharma in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.85. Arbutus Biopharma's value of 25.10% is 69% above this benchmark. While the company's 10-year median is 11.60 vs. the industry median of 14.85, Arbutus Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,136 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arbutus Biopharma's current 3-Year EBITDA Growth Rate of 25.10% is 69% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Arbutus Biopharma and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arbutus Biopharma's current 3-Year EBITDA Growth Rate is 25.10%, which is 116% above median its own 10-year median of 11.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arbutus Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Arbutus Biopharma (ABUS) is currently considered Possible Value Trap. The stock's GF Value™ is $50.40, compared to a current price of $4.36 — trading 91.3% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 25.10%, which is 116% above median its 10-year median of 11.60 and 69% above the Biotechnology industry median of 14.85. Arbutus Biopharma's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Arbutus Biopharma (ABUS), the current 3-Year EBITDA Growth Rate is 25.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arbutus Biopharma (ABUS) Overvalued in 2026?
Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued.
The current stock price of $4.36 is trading 91.3% below its estimated GF Value™ of $50.40.
GuruFocus considers Arbutus Biopharma to be Possible Value Trap.
Key valuation signals for ABUS:
3-Year EBITDA Growth Rate: 25.10% (116% above median its 10-year median of 11.60)
GF Value™: $50.40 vs. price of $4.36 (91.3% below fair value)
Industry Position: 69% above the Biotechnology median (#439 of 1136)
No single metric tells the full story. See the ABUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
51GF Score
Get the complete analysis for ABUS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABUS has been successfully added to your 
